66 related articles for article (PubMed ID: 2949756)
41. [Peripheral neuropathy in relation to LAV/HTLV III retrovirus infection. A clinical, anatomical and immunological study. 5 cases].
Leport C; Chaunu MP; Sicre J; Brun-Vezinet F; Hauw JJ; Vildé JL
Presse Med; 1987 Jan; 16(2):55-8. PubMed ID: 3027690
[TBL] [Abstract][Full Text] [Related]
42. [Interstitial lymphoid pneumonia and polyadenopathies in patients infected with the LAV/HTLV III virus].
Couderc LJ; Hervé P; Solal-Celigny P; Herman D; D'Agay MF; Morinet F; Matheron S; Rabian C; Caubarrere I; Clauvel JP
Presse Med; 1986 Jun; 15(24):1127-30. PubMed ID: 2942907
[TBL] [Abstract][Full Text] [Related]
43. Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease.
Andrieu JM; Even P; Venet A; Tourani JM; Stern M; Lowenstein W; Audroin C; Eme D; Masson D; Sors H
Clin Immunol Immunopathol; 1988 May; 47(2):181-98. PubMed ID: 3258211
[TBL] [Abstract][Full Text] [Related]
44. In vitro suppression of HTLV-III/LAV infectivity by a combination of acyclovir and suramin.
Resnick L; Markham PD; Veren K; Salahuddin SZ; Gallo RC
J Infect Dis; 1986 Dec; 154(6):1027-30. PubMed ID: 3640792
[No Abstract] [Full Text] [Related]
45. Ultrastructural markers and interferon levels in HIV-positive individuals treated with D-penicillamine.
Orenstein JM; Schulof RS
Prog AIDS Pathol; 1989; 1():41-50. PubMed ID: 2485011
[No Abstract] [Full Text] [Related]
46. [On the therapy of sarcoidosis stage III by D-penicillamine (author's transl)].
Behrend H
Z Erkr Atmungsorgane; 1977 Aug; 149(2):173-8. PubMed ID: 610091
[No Abstract] [Full Text] [Related]
47. Prolonged antiviral activity of D-penicillamine in human immunodeficiency virus-infected homosexual men.
Scheib RG; Parenti DM; Simon GL; Courtless JW; Schulof RS; Sarin PS; Chandra P
Am J Med; 1987 Sep; 83(3):608. PubMed ID: 3661606
[No Abstract] [Full Text] [Related]
48. [Lymphocytes of perypheral blood in P.R. under treatment with penicillamine D].
Fargas R; Menchón M; Santamaría A; Barceló P
Rev Esp Reum Enferm Osteoartic; 1975; 18(3):190-201. PubMed ID: 1081252
[No Abstract] [Full Text] [Related]
49. Ribavirin in HTLV-III/LAV infection of infants.
Blanche S; Fischer A; le Deist F; Griscelli C; Guetard D; Favier V; Montagnier L
Lancet; 1986 Apr; 1(8485):863. PubMed ID: 2870349
[No Abstract] [Full Text] [Related]
50. Clinical trial of tolerance of HPA-23 in patients with acquired immune deficiency syndrome.
Moskovitz BL
Antimicrob Agents Chemother; 1988 Sep; 32(9):1300-3. PubMed ID: 3058016
[TBL] [Abstract][Full Text] [Related]
51. Clinical pharmacokinetics of D-penicillamine.
Netter P; Bannwarth B; Péré P; Nicolas A
Clin Pharmacokinet; 1987 Nov; 13(5):317-33. PubMed ID: 3319347
[TBL] [Abstract][Full Text] [Related]
52. Antiviral therapy in human immunodeficiency virus infection.
Sandström E
Drugs; 1989 Sep; 38(3):417-50. PubMed ID: 2680436
[TBL] [Abstract][Full Text] [Related]
53. Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine.
Roederer M; Staal FJ; Raju PA; Ela SW; Herzenberg LA; Herzenberg LA
Proc Natl Acad Sci U S A; 1990 Jun; 87(12):4884-8. PubMed ID: 2112750
[TBL] [Abstract][Full Text] [Related]
54. Selective inhibition of replication of the AIDS-associated virus HTLV-III/LAV by synthetic D-penicillamine.
Chandra P; Sarin PS
Arzneimittelforschung; 1986 Feb; 36(2):184-6. PubMed ID: 3008768
[TBL] [Abstract][Full Text] [Related]
55. Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen.
McDougal JS; Mawle A; Cort SP; Nicholson JK; Cross GD; Scheppler-Campbell JA; Hicks D; Sligh J
J Immunol; 1985 Nov; 135(5):3151-62. PubMed ID: 2995487
[TBL] [Abstract][Full Text] [Related]
56. Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virus.
Yarchoan R; Redfield RR; Broder S
J Clin Invest; 1986 Aug; 78(2):439-47. PubMed ID: 3016028
[TBL] [Abstract][Full Text] [Related]
57. Deficiency of the autologous mixed lymphocyte reaction in patients with classic hemophilia treated with commercial factor VIII concentrate. Correlation with T cell subset distribution, antibodies to lymphadenopathy-associated or human T lymphotropic virus, and analysis of the cellular basis of the deficiency.
Smolen JS; Bettelheim P; Köller U; McDougal S; Graninger W; Luger TA; Knapp W; Lechner K
J Clin Invest; 1985 Jun; 75(6):1828-34. PubMed ID: 2989334
[TBL] [Abstract][Full Text] [Related]
58. Clinical, immunological, and virological aspects in Japanese hemophiliacs and AIDS patients.
Abe T
AIDS Res; 1986 Dec; 2 Suppl 1():S141-6. PubMed ID: 3103637
[TBL] [Abstract][Full Text] [Related]
59. Treatment of HTLV-III/LAV-infected patients with D-penicillamine.
Schulof RS; Scheib RG; Parenti DM; Simon GL; DiGioia RA; Paxton HM; Sztein MB; Chandra P; Courtless JW; Taguchi YT
Arzneimittelforschung; 1986 Oct; 36(10):1531-4. PubMed ID: 2949756
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
